Contrary to assumptions, once-a-day pills for combating HIV are actually less expensive than multi-tablet regimens and also offer an added bonus — patient adherence is greater, which suggests healthier outcomes, according to a new analysis of pharmacy claims.

To wit, overall medicine costs for patient taking single-tablet regimens were $6,100 less a year when compared regimens requiring multiple pills, among those who were taking the pills as they should. On average, health plans would save $4,162 per patient each year if they switched to clinically equivalent single-tablet regimens. Meanwhile, patient adherence was nearly 75 percent among those taking once-daily pills versus 65 percent for those on multi-tablet regimens.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • After this careful explanation, the takeaway seems to be “spend more, save more.” (More money, more people … other?) This post will need a second or third reading to fully understand this conundrum.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy